Comprehensive analysis of the claims and U.S. patent landscape for US 11,572,543
US Patent 11,572,543 is a granted U.S. patent that anchors a defined claim set and typically creates a licensing and enforcement perimeter around the technology recited in the independent claims and their dependent claim network. The patent landscape around US 11,572,543 depends on (1) the exact claim scope in the granted claims, (2) the priority chain and prosecution history, (3) the patent family’s continuations and related method or formulation patents, and (4) whether the claims map cleanly onto FDA-listed products and commercial manufacturing routes.
No actionable claim text, inventors/assignees, publication number family links, or claim-by-claim scope indicators were provided, so a complete and accurate analysis cannot be produced.
What claims are in US 11,572,543 and what do they cover?
Answer: Not determinable from the provided input.
- Required for a complete claim analysis:
- The independent claim(s) as granted (exact wording).
- Key dependent claims that narrow structure, composition, process parameters, dosage forms, biomarkers, patient selection, or administration steps.
- Definitions embedded in the specification (terms like “effective amount,” “substituted,” “therapeutically active,” “pharmaceutical composition,” or process step sequencing).
- Claim construction markers in the specification (examples, embodiments, ranges, and preferred limits).
H3: Which independent claims drive enforceable scope?
- Not determinable without the granted claim text.
H3: What are the critical limitation types (composition, method, use, device, process)?
- Not determinable without the granted claim text.
H3: How do dependent claims likely create fallback positions?
- Not determinable without claim set access.
How strong is the patent estate around US 11,572,543 (continuations, siblings, and related patents)?
Answer: Not determinable from the provided input.
A defensible estate strength assessment requires mapping:
- Patent family members sharing the same priority.
- Continuations, divisionals, and related continuations-in-part.
- Terminal disclaimers and adjustment impacts.
- Co-owned or licensed portfolios around the same active ingredient, formulation platform, manufacturing method, or medical indication.
H3: How many family members exist and where are they filed?
- Not determinable from the provided input.
H3: Do prosecution continuations suggest breadth or narrowing?
- Not determinable without file history access.
H3: Are there related patents that compete for the same “commercial map” (Orange Book listing, device component, process steps)?
- Not determinable from the provided input.
What patents overlap US 11,572,543 by priority date and technical subject matter?
Answer: Not determinable from the provided input.
Overlap analysis requires:
- Identifying the drug/active ingredient and technical field.
- Locating other U.S. patents with similar claims or shared embodiments.
- Comparing claim elements across:
- composition/formulation patents
- method-of-treatment/use patents
- manufacturing/process patents
- device/delivery patents
- biomarker and patient selection patents
H3: Which earlier publications likely anticipate or render obvious?
- Not determinable from the provided input.
H3: Which later filings likely “cover improvements” or “design-arounds”?
- Not determinable from the provided input.
When does US 11,572,543 expire and how do PTA and disclaimers affect exclusivity?
Answer: Not determinable from the provided input.
A correct expiration schedule requires:
- Earliest effective filing date (priority-adjusted).
- Any terminal disclaimer term or patent term adjustments.
- Whether the patent is subject to any exclusivity regime constraints (rare outside drug/device context, but terminal disclaimer and PTA can move the end date).
H3: What is the earliest priority date and the presumptive 20-year term?
- Not determinable from the provided input.
H3: What is the adjusted expiration date with PTA/terminal disclaimer?
- Not determinable from the provided input.
H3: Does the patent term hinge on maintenance status?
- Not determinable from the provided input.
What is the Orange Book status of US 11,572,543 relevant products?
Answer: Not determinable from the provided input.
Orange Book mapping requires:
- The FDA application number(s) and NDA/BLA/ANDA link to the patented product(s).
- Patent listing type: drug substance, drug product, and method of use.
- Listed expiration dates and any “carve-out” conditions for methods of use.
H3: Is US 11,572,543 listed as drug substance, drug product, or method-of-use?
- Not determinable from the provided input.
H3: Which FDA application(s) are tied to the patent listing?
- Not determinable from the provided input.
Which generic or biosimilar challenges target the same claim scope as US 11,572,543 (Paragraph IV and BPCIA)?
Answer: Not determinable from the provided input.
To identify challenges, the analysis must link:
- The specific FDA application(s) and patent list numbers.
- The ANDA or BLA applicants and filing dates.
- The notice letters and court dockets.
- Whether the challenge is to the “listed patent” and what grounds (infringement, invalidity categories under 35 USC 102/103/112/101).
H3: What Paragraph IV certifications are filed against the listed patent(s)?
- Not determinable from the provided input.
H3: Are there biosimilar challenges under BPCIA that track the same patent family?
- Not determinable from the provided input.
What patent litigation affects US 11,572,543 (district courts, PTAB, ITC)?
Answer: Not determinable from the provided input.
A litigation map needs:
- Parties and case numbers.
- Asserted claims and claim construction outcomes.
- Settlement terms that allocate launch timelines, royalties, or covenant-not-to-sue scope.
- Post-grant review events (IPR/PGR) and whether claims were narrowed or canceled.
H3: Which asserted claim elements are disputed in court?
- Not determinable from the provided input.
H3: Did PTAB rulings narrow US 11,572,543’s enforceable claim set?
- Not determinable from the provided input.
How does US 11,572,543 compare with competitor patent estates for the same drug or platform?
Answer: Not determinable from the provided input.
A credible comparison requires:
- Identifying the marketed product(s) practicing the technology covered by US 11,572,543.
- Collecting competitor families, their earliest priorities, and claim scopes.
- Scoring “design-around difficulty” across:
- required structural features
- process parameters or yield/purity limits
- dosage regimen or patient selection criteria
H3: Which competitor claims are closest to US 11,572,543?
- Not determinable from the provided input.
H3: Where are the highest infringement risk points for generics or follow-on development?
- Not determinable from the provided input.
What formulations are protected by US 11,572,543 (drug product scope)?
Answer: Not determinable from the provided input.
Formulation protection assessment needs:
- Claimed excipient systems, salts, polymorphs, amorphous forms, particle sizes, release profiles, and manufacturing steps.
- Claim language for composition ranges (w/w percent ranges, pH windows, viscosity, osmolarity).
- Any “Markush” or functional limitations that broaden scope.
H3: Are there polymorph, particle size, or solid-state form limitations?
- Not determinable from the provided input.
H3: Are there release-controlled or stability-based limitations?
- Not determinable from the provided input.
What method-of-use patents are bundled with US 11,572,543 (clinical endpoints, dosing, patient selection)?
Answer: Not determinable from the provided input.
Method-of-use analysis requires:
- The claimed therapeutic indication, disease state, biomarker status, dosage regimen, and administration route.
- Whether the claims are directed to specific patient subsets or clinical endpoints.
- Relationship to FDA labeling (label match is central to infringement risk).
H3: Is infringement tied to specific biomarker tests or stratification?
- Not determinable from the provided input.
H3: What dosing regimen parameters are actually claimed?
- Not determinable from the provided input.
What manufacturing or process barriers exist because of US 11,572,543?
Answer: Not determinable from the provided input.
Process barriers require:
- Claim scope for mixing, heating/cooling, pH control, solvent selection, crystallization conditions, purification methods, and yield/purity thresholds.
- Whether claims cover “how to make” or “what is made” (structural vs process limitations).
- Potential design-around routes that avoid the claimed process parameters.
H3: Do claims cover intermediate compositions or only final product?
- Not determinable from the provided input.
H3: Are the process parameters narrow ranges that enable easy workarounds?
- Not determinable from the provided input.
Key Takeaways
- No claim-level scope, expiration mechanics, prosecution history, Orange Book listing status, litigation posture, or family/estate mapping can be stated accurately without the patent’s claim text and bibliographic data.
- A complete critical analysis requires the granted claim set and at least the patent’s assignee/inventor and family members to establish infringement coverage and competitive risk.
FAQs
- How do independent and dependent claim structures in U.S. patents typically affect design-around feasibility?
- What factors determine adjusted expiration dates in U.S. patents with PTA and terminal disclaimers?
- How is a drug patent categorized in the Orange Book (drug substance vs drug product vs method of use) and why does it matter for ANDA challenges?
- What claim elements most commonly break infringement for method-of-use patents (label mismatch, biomarker criteria, dosage regimen deviations)?
- How do IPR/PTAB outcomes usually change enforceability of pharmaceutical patents at the claim level?
References
- Not provided, because no source patent text, prosecution records, Orange Book listings, FDA application linkages, litigation dockets, or family member identifiers were provided.
